Coverage of 13-Valent Pneumococcal Conjugate Vaccine Among Children 0-15 Months of Age - 9 Provinces, China, 2019-2021.

China CDC Weekly Pub Date : 2023-04-28 DOI:10.46234/ccdcw2023.072

Lijun Liu, Zhaonan Zhang, Xixi Zhang, Changsha Xu, Yifan Song, Li Li, Jiakai Ye, Zhiguo Wang, Hui Liang, Weiyan Zhang, Ling Lin, Ning Li, Shujun Zhang, Qianli Ma, Wen Du, Yongzhuo Jiao, Lingsheng Cao, Qi Qi, Lei Cao, Wenzhou Yu

{"title":"Coverage of 13-Valent Pneumococcal Conjugate Vaccine Among Children 0-15 Months of Age - 9 Provinces, China, 2019-2021.","authors":"Lijun Liu, Zhaonan Zhang, Xixi Zhang, Changsha Xu, Yifan Song, Li Li, Jiakai Ye, Zhiguo Wang, Hui Liang, Weiyan Zhang, Ling Lin, Ning Li, Shujun Zhang, Qianli Ma, Wen Du, Yongzhuo Jiao, Lingsheng Cao, Qi Qi, Lei Cao, Wenzhou Yu","doi":"10.46234/ccdcw2023.072","DOIUrl":null,"url":null,"abstract":"What is already known on this topic?: Limited data exist regarding the coverage of the 13-valent pneumococcal conjugate vaccine (PCV13) in China. A lack of official statistics, coupled with an insufficient body of published literature, hinders the accurate depiction of the current situation.What is added by this report?: This study investigated the utilization of PCV13 and estimated its coverage in nine provinces across eastern, central, and western China between 2019 and 2021. Despite an annual increase in PCV13 usage during this period, the overall coverage remained suboptimal.What are the implications for public health practice?: Consideration should be given to incorporating vaccines into the Expanded Program of Immunization, reducing vaccine prices, and addressing the vaccination coverage gap between eastern and western regions when there is an adequate supply of PCV13, particularly with domestic vaccines.","PeriodicalId":9867,"journal":{"name":"China CDC Weekly","volume":"5 17","pages":"379-384"},"PeriodicalIF":0.0000,"publicationDate":"2023-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/c3/03/ccdcw-5-17-379.PMC10184383.pdf","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"China CDC Weekly","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.46234/ccdcw2023.072","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 3

Abstract

What is already known on this topic?: Limited data exist regarding the coverage of the 13-valent pneumococcal conjugate vaccine (PCV13) in China. A lack of official statistics, coupled with an insufficient body of published literature, hinders the accurate depiction of the current situation.

What is added by this report?: This study investigated the utilization of PCV13 and estimated its coverage in nine provinces across eastern, central, and western China between 2019 and 2021. Despite an annual increase in PCV13 usage during this period, the overall coverage remained suboptimal.

What are the implications for public health practice?: Consideration should be given to incorporating vaccines into the Expanded Program of Immunization, reducing vaccine prices, and addressing the vaccination coverage gap between eastern and western regions when there is an adequate supply of PCV13, particularly with domestic vaccines.

查看原文本刊更多论文

2019-2021年中国9个省份0-15月龄儿童13价肺炎球菌结合疫苗接种率

关于这个话题我们已经知道了什么?关于13价肺炎球菌结合疫苗(PCV13)在中国的覆盖率数据有限。由于缺乏官方统计数据，再加上发表的文献不足，妨碍了对当前情况的准确描述。这份报告增加了什么内容?本研究调查了2019年至2021年中国东部、中部和西部9个省份PCV13的使用情况，并估计了其覆盖范围。尽管在此期间PCV13的使用量每年都在增加，但总体覆盖率仍然不理想。这对公共卫生实践有什么影响?应考虑将疫苗纳入扩大免疫规划，降低疫苗价格，并在PCV13供应充足的情况下，特别是使用国内疫苗，解决东部和西部地区之间的疫苗接种覆盖率差距。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

China CDC Weekly

自引率

0.00%

发文量